Clinical Trial Update: An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) [Phase 2]

View source ↗

Summary

An open-label Phase 2 safety study of memantine in pediatric patients with autism spectrum disorders has completed, with results posted in 2014. The study evalu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asperger Syndrome
• Autism Spectrum Disorder
• Autistic Disorder
• Pervasive Developmental Disorder Not Otherwise Specified

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: Forest Laboratories | Conditions: Autism Spectrum Disorder (ASD), Autism | Phase 2 | Status: COMPLETED | Results posted: 2014-08-07